Download PDF
Aktuelle Neurologie 2005; 32: 56-60
DOI: 10.1055/s-2004-834698
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Subkutane Dauerinfusion mit Apomorphin

Continuous Subcutaneous Apomorphine InfusionS.  M.  Boesch1 , W.  Poewe1
  • 1Univ.-Klinik für Neurologie, Medizinische Universität Innsbruck
Further Information

Publication History

Publication Date:
26 April 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Effekte einer kontinuierlichen s. c. Anwendung von Apomorphin mittels Minipumpe wurden erst in den letzten Jahren systematisch untersucht. Eine Vielzahl von Studien mit kleinen Patientenzahlen konnte zeigen, dass eine s. c. Infusionstherapie mit Apomorphin zu einer Reduktion der täglichen „Off”-Zeiten um mehr als 50 % führt. Dieser Effekt überragt die normalerweise bei oraler Add-on-Therapie mit Dopaminagonisten und COMT-Inhibitoren beobachtete Reduktion bei weitem. Langzeitstudien mit einer Dauer bis zu acht Jahren belegen einen anhaltenden Effekt der oben beschriebenen Apomorphinwirkung. Darüber hinaus scheint vor allem eine Monotherapie mit kontinuierlicher s. c. Apomorphinapplikation zu einer deutlichen Reduktion vorbestehender Dyskinesien zu führen. Die wichtigsten Nebenwirkungen einer s. c. Apomorphinanwendung bestehen in einer individuell unterschiedlichen Hautverträglichkeit, während neuropsychiatrische Nebenwirkungen weniger häufig zu beobachten sind. Angesichts der guten und anhaltenden Wirkung von Apomorphin insbesondere bei kontinuierlicher s. c. Anwendung in der Therapie L-Dopa-induzierter Langzeitkomplikationen bei der Parkinson-Krankheit wird dieser Therapieansatz derzeit zu wenig genutzt.

Abstract

Continuous subcutaneous administration of apomorphine via minipumpe, in PD has only recently become subject of systematic study. A number of small scale clinical trials have unequivocally shown that continuous apomorphine infusions can reduce daily off-time by more than 50 %, which appears to be a stronger effect than the one generally seen with add-on therapy with oral dopamine agonists and COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. Moreover, there is clinical evidence that monotherapy with continuous s. c. apomorphine infusions is associated with a marked reduction of pre-existing levodopa induced dyskinesias. The main side-effects of s. c. apomorphine treatment are related to cutaneous tolerability problems while neuropsychiatric problems are less frequent. In light of the marked efficacy of s. c. apomorphine treatment in PD with long-term complications this therapeutic approach seems to deserve more widespread clinical use.

Literatur

  • 1 Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.  Brain. 2000;  123 2297-2305
    CrossrefPubMedGoogle Scholar
  • 2 Marsden C D, Parkes J D, Quinn N. Fluctuations and disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S (eds) Movement Disorders. London; Butterworth Scientific 1982: 96-122
    Google Scholar
  • 3 Poewe W, Wenning G K. The natural history of Parkinson's disease.  Ann Neurol. 1998;  44 (3, Suppl 1) 1-9
    CrossrefPubMedGoogle Scholar
  • 4 Chase T N, Justin D O. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.  Ann Neurol. 2000;  47 (suppl 1) S122-S130
    CrossrefPubMedGoogle Scholar
  • 5 Nutt J G, Obeso J A, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease.  Trends Neurosci. 2000;  23 (suppl) S109-S115
    CrossrefPubMedGoogle Scholar
  • 6 Schwab R S, Amador L V, Lettin J Y. Apomorphine in Parkinson's disease.  Trans Am Neurol assoc. 1951;  76 251-253
    PubMedGoogle Scholar
  • 7 Struppler A, Üexküll T von. Untersuchungen über die Wirkungsweise des Apomorphins auf den Parkinsontremor.  Z Klin Med. 1953;  152 46-57
    PubMedGoogle Scholar
  • 8 Cotzias G C, Papavasiliou P S, Fehling C. et al . Similarities between neurological effects of L-Dopa and of apomorphine.  N Engl J Med. 1970;  282 31-33
    PubMedGoogle Scholar
  • 9 Cotzias G C, Papavasiliou P S, Tolosa E S. et al . Treatment of Parkinson's disease with apomorphines.  N Engl J Med. 1976;  294 567-572
    PubMedGoogle Scholar
  • 10 Stibe C M, Lees A J, Kempster P A, Stern G M. Subcutaneous apomorphine in parkinsonian on-off oscillations.  Lancet. 1988;  1 403-406
    PubMedGoogle Scholar
  • 11 Kempster P A, Frankel J P, Stern G M, Lesse A J. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 1004-1007
    PubMedGoogle Scholar
  • 12 Steiger M J, Quinn N P, Marsden C D. The clinical use of apomorphine in Parkinson's disease.  J Neurol. 1992;  239 389-393
    PubMedGoogle Scholar
  • 13 Poewe W, Kleedorfer B, Wagner M, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease in 20 patients.  Neurology. 1991;  41 172-173
    PubMedGoogle Scholar
  • 14 Hughes A J, Bishop S, Kleedorfer B. et al . Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to 5 year.  Mov Disord. 1993;  6 165-170
    PubMedGoogle Scholar
  • 15 Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long-term follow up.  J Neurol Neurosurg Psychiatr. 1998;  65 709-716
    CrossrefPubMedGoogle Scholar
  • 16 Colzi A, Turner K, Lees A J. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1998;  64 573-576
    CrossrefPubMedGoogle Scholar
  • 17 Wenning G K, Bösch S, Luginger E. et al . Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in Parkinson's disease.  Adv Neurol. 1999;  80 545-548
    PubMedGoogle Scholar
  • 18 Manson A J, Turner K, Lees A J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.  Mov Disord. 2002;  17 1235-1241
    CrossrefPubMedGoogle Scholar
  • 19 Gancher S T, Nutt J G, Woodward W R. Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance.  Mov Disord. 1995;  10 37-43
    CrossrefPubMedGoogle Scholar
  • 20 Poewe W, Kleedorfer B, Wagner M. et al . Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.  Adv Neurol. 1993;  60 656-659
    PubMedGoogle Scholar
  • 21 Guttmann M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.  Neurology. 1997;  49 1060-1065
    PubMedGoogle Scholar
  • 22 Inzelberg R, Nisipeanu P, Rabey J M. et al . Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.  Neurology. 1996;  47 785-788
    PubMedGoogle Scholar
  • 23 Olanow C W, Fahn S, Muenter M. et al . A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.  Mov Disord. 1994;  9 40-47
    CrossrefPubMedGoogle Scholar
  • 24 Olanow C W, Alberts M J. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease.  Clin Neuropharmacol. 1987;  10 178-185
    PubMedGoogle Scholar
  • 25 Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease.  Adv Neurol. 1987;  45 551-554
    PubMedGoogle Scholar
  • 26 Diamond S G, Markham C H, Treciokas L J. Double-blind trial of pergolide for Parkinson's disease.  Neurology. 1985;  35 291-295
    PubMedGoogle Scholar
  • 27 Pinter M M, Pogarell O, Oertel W H. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo controlled, randomised, multicentre study.  J Neurol Neurosurg Psychiatry. 1999;  66 436-441
    CrossrefPubMedGoogle Scholar
  • 28 Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study.  Neurology. 1997;  49 162-168
    CrossrefPubMedGoogle Scholar
  • 29 Lieberman A, Olanow C W, Sethi K. et al . A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.  Neurology. 1998;  51 1057-1062
    PubMedGoogle Scholar
  • 30 Geminiani G, Fetoni V, Genitrini S. et al . Cabergoline in Parkinson's disease complicated by motor fluctuations.  Mov Disord. 1996;  11 495-500
    CrossrefPubMedGoogle Scholar
  • 31 Steiger M J, El-Debas T, Anderson T. et al . Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.  J Neurol. 1996;  243 68-72
    PubMedGoogle Scholar
  • 32 Kurth M C, Adler C H, Hilaire M S. et al . Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomised, placebo-controlled trial. Tolcapone fluctuator study group I.  Neurology. 1997;  48 81-87
    PubMedGoogle Scholar
  • 33 Myllylä W, Jackson M, Larsen J P, Baas H,. Tolcapone International Parkinson's Disease Study (TIPS) Group I . Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with wearing-off phenomenon: a multicenter, double-blind, randomised, placebo-controlled trial.  Eur J Neurol. 1997;  4 333-341
    PubMedGoogle Scholar
  • 34 Rajput A H, Martin W, Saint-Hilaire M H. et al . Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: a double-blind, placebo-controlled, multicenter trial.  Neurology. 1997;  49 1066-1071
    PubMedGoogle Scholar
  • 35 Baas H, Beiske A G, Ghika J. et al . Catechol-O-methyltransferase inhibition with tolcapone reduces the wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients.  J Neurol Neurosurg Psychiatry. 1997;  63 421-428
    PubMedGoogle Scholar
  • 36 Adler C H, Singer C, O'Brien C. et al . Randomised, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tolcapone fluctuator study group II.  Arch Neurol. 1998;  55 1089-1095
    CrossrefPubMedGoogle Scholar
  • 37 Parkinson Study Group . Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients.  Ann Neurol. 1997;  42 747-755
    CrossrefPubMedGoogle Scholar
  • 38 Rinne U K, Larsen J P, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.  Neurology. 1998;  51 1309-1314
    PubMedGoogle Scholar
  • 39 Duby S E, Cotzias G C, Papavasiliou P S, Lawrence W H. Injected apomorphine and orally administered levodopa in parkinsonism.  Arch Neurol. 1972;  27 474-480
    PubMedGoogle Scholar
  • 40 O'Sullivan J D, Hughes A J. Apomorphine-induced penile erections in Parkinson's disease.  Mov Disord. 1998;  13 536-539
    CrossrefPubMedGoogle Scholar
  • 41 Kreczy-Kleedorfer B, Wagner M, Bösch S, Poewe W. Long-term results of continuous apomorphine pump therapy in patients with advanced Parkinson's disease.  Nervenarzt. 1993;  64 221-225
    PubMedGoogle Scholar
  • 42 Poewe W, Wenning G K. Apomorphine: an underutilized therapy for Parkinson's disease. Review.  Mov Disord. 2000;  15 789-794
    CrossrefPubMedGoogle Scholar
  • 43 Frankel J P, Lees A J, Kempster P A, Stern G M. Subcutaneous apomorphine in the treatment of Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1990;  53 96-101
    CrossrefPubMedGoogle Scholar
  • 44 Pollak P, Champay A S, Hommel M. et al . Subcutaneous apomorphine in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1989;  52 544
    PubMedGoogle Scholar
  • 45 Stocchi F, Bramante L, Monge A. et al . Apomorphine and lisuride infusion. A comparative chronic study.  Adv Neurol. 1993;  60 653-655
    PubMedGoogle Scholar

Prof. Werner Poewe

Univ.-Klinik für Neurologie · Medizinische Universität Innsbruck

Anichstraße 35

6020 Innsbruck · Österreich

Email: werner.poewe@uibk.ac.at

      >